Yttrium 90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell LymphomaLeo I. Gordon, Christine A. White, Katie D. Vo et al.|Clinical Lymphoma|2004Cited by 121
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trialMeletios Α. Dimopoulos, Shaji Kumar, Fredrik Schjesvold et al.|Blood Cancer Journal|2022Cited by 21
Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)Toni K. Choueiri, Neeraj Agarwal, Yousef Zakharia et al.|The Oncologist|2021Cited by 10